What is the recommended management for FIGO stage I endometrioid carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of FIGO Stage I Endometrioid Carcinoma

For FIGO stage I endometrioid carcinoma, perform total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy using indocyanine green cervical injection, then stratify adjuvant therapy based on molecular classification combined with grade, depth of myometrial invasion, and lymphovascular space invasion. 1

Primary Surgical Management

The cornerstone of treatment is minimally invasive surgery (laparoscopic or robotic approach preferred) consisting of 2, 1:

  • Total hysterectomy with bilateral salpingo-oophorectomy
  • Sentinel lymph node biopsy using indocyanine green with cervical injection (preferred detection method)
  • If sentinel nodes not visualized bilaterally, perform side-specific systematic pelvic lymphadenectomy for high-intermediate or high-risk patients
  • All sentinel lymph nodes undergo ultrastaging (sectioning at 50-250µ intervals with H&E and immunohistochemistry)

Critical surgical caveat: Avoid any intraperitoneal tumor spillage, rupture, or morcellation—even in a bag—as this worsens prognosis 1. If vaginal extraction risks uterine rupture, use mini-laparotomy or endobag extraction.

Risk Stratification Framework

Risk classification now integrates molecular subtyping (mandatory for optimal management) with traditional clinicopathologic factors 1, 3:

Molecular Classification (Four Subgroups):

  1. POLEmut (POLE ultramutated) - excellent prognosis
  2. MMRd (mismatch repair deficient) - intermediate prognosis
  3. NSMP (no specific molecular profile) - requires estrogen receptor (ER) assessment
  4. p53abn (p53 abnormal) - poorest prognosis

Traditional Risk Factors:

  • Depth of myometrial invasion (<50% vs ≥50%)
  • Tumor grade (1-2 vs 3)
  • Lymphovascular space invasion (absent, focal, or substantial)
  • Cervical stromal involvement

Adjuvant Therapy Algorithm by Risk Group

Low-Risk Disease (Stage IA Grade 1-2, POLEmut, or NSMP ER-positive with favorable features):

Observation only - no adjuvant therapy required 2, 1

The evidence is unequivocal: multiple randomized trials show no survival benefit from adjuvant radiation in this group 2.

Intermediate-Risk Disease (Stage IA Grade 3 or Stage IB Grade 1-2):

Vaginal brachytherapy alone is the preferred option 2

The PORTEC-2 trial demonstrated vaginal brachytherapy provides equivalent locoregional control to external beam radiation with superior quality of life 2. External beam radiation reduces pelvic recurrence but does not improve overall survival 4, 2.

High-Intermediate Risk (Stage IB Grade 3, age ≥60, deep invasion):

Vaginal brachytherapy is standard, with consideration of pelvic external beam radiation if multiple adverse factors present 2, 4

For patients with two or more major risk factors (age ≥60 years, deep myometrial invasion, grade 3), locoregional relapse exceeds 15%, warranting more aggressive local therapy 4, 5.

High-Risk Disease (Stage IB Grade 3 with substantial LVSI, or p53abn molecular subtype):

Combination chemotherapy (carboplatin/paclitaxel) with or without sequential radiation 2, 4

Platinum-based chemotherapy significantly improves progression-free and overall survival compared to radiation alone in high-risk stage I disease 4. The p53abn molecular subgroup has particularly poor prognosis requiring systemic therapy even in early-stage disease 3, 6.

Molecular Subtype-Specific Considerations

POLEmut Tumors:

  • Observation regardless of stage or grade 1, 3
  • Excellent prognosis with high salvage rates even if recurrence occurs
  • No adjuvant therapy recommended even for stage IB grade 3 disease

MMRd Tumors:

  • Grade has limited prognostic relevance within this subgroup 7
  • For stage I disease: observation or vaginal brachytherapy based on other risk factors
  • Tumor grade should not drive treatment escalation in MMRd tumors 1

NSMP Tumors:

  • ER status is critical: ER-negative tumors have significantly increased recurrence risk 1, 3
  • ER-positive with favorable features: observation
  • ER-negative or substantial LVSI: consider intensified therapy 7

p53abn Tumors:

  • Highest recurrence rate (30.3%) with peak hazard at 16.8 months 6
  • Frequently present with simultaneous multi-site recurrences
  • Require systemic chemotherapy even for stage IA disease 3, 6
  • Consider combination chemoradiation for stage IB

Special Populations

Premenopausal Women <45 Years (Stage IA1-2, Low Risk):

Ovarian preservation can be considered if:

  • Low molecular risk (not p53abn)
  • No hereditary cancer syndrome (Lynch, BRCA)
  • Perform bilateral salpingectomy if ovaries preserved 1

Medically Unfit Patients:

If surgery contraindicated, primary radiation therapy (external beam + brachytherapy) is an alternative, though inferior to surgical management 8.

Common Pitfalls to Avoid

  1. Performing systematic lymphadenectomy in all patients: Two large randomized trials (ASTEC, Italian study) showed no survival benefit from routine lymphadenectomy in stage I disease 2. Sentinel node biopsy is the preferred staging approach.

  2. Over-treating POLEmut tumors: These have excellent prognosis regardless of grade—do not escalate therapy based on grade 3 histology alone.

  3. Under-treating p53abn tumors: Even stage IA p53abn requires systemic therapy due to high distant recurrence risk.

  4. Ignoring ER status in NSMP tumors: ER-negative NSMP behaves more aggressively and requires treatment intensification 1, 3.

  5. Using external beam radiation for intermediate-risk disease: Vaginal brachytherapy provides equivalent control with better quality of life 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.